EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta Evidence indicates risk of serious inflammatory brain disorders The European Medicines Agency (EMA) has recommended the immediate suspension and…
Read More
News Archive • Page 4 of 8 • Fortissa
UK PM signals intent to remain with EMA Prime Minister Theresa May has unveiled the government’s desire for the UK to remain part of the European Medicines Agency following its…
AZ’ Forxiga to be reviewed for diabetes type I The European Medicines Agency has accepted AstraZeneca’s filing for Forxiga as a treatment for diabetes type I. The submission contains data…
Natural doesn’t mean safe – herbal medicines found to contain steroids People who may have purchased Yiganerjing Cream are urged to discontinue use immediately as it contains an undisclosed steroid…
MHRA update to pharmaceutical companies on exit preparations The European Council formally agreed on 15 December that sufficient progress has been made to move on to the second stage of…
Dispensing defence one of Hunt’s ‘ground-breaking’ plans to end errors Health secretary Jeremy Hunt has set out three “ground-breaking” measures to tackle 200 million medication errors across the NHS each…
Aquilon Medical Nebulisers: people urged to stop use immediately People and healthcare organisations are being urged to check if they have the affected Aquilon series of nebulisers. Following withdrawal of CE…
Class 4 Medicines Defect Information: Bleo-Kyowa, powder for solution for injection, 15,000 IU Caution in Use Distribute to Hospital Pharmacy, Ward, Chemotherapy Unit and Clinic Level. (EL (18) A/05) Product…
AstraZeneca’s Imfinzi breaks new I-O ground with landmark $1B lung cancer nod Backed by convincing survival data, AstraZeneca’s Imfinzi is breaking out on its own. Friday, the drug snagged an…
MHRA suspends new prescriptions of fibroid drug Esmya The UK medicines regulator has said that new patients should not be prescribed Gedeon Richter’s Esmya while an EU safety probe is…